ArticleCureus2025
Clinical and Echocardiographic Profile of Patients With Heart Failure With Reduced Ejection Fraction: A Retrospective Outcome Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- VERINA: A Phase IV Prospective Multicenter Study of Vericiguat in Indian Patients with Worsening Heart Failure and Reduced Ejection Fraction.Cardiology and therapy · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeart failure with reduced ejection fraction (HFrEF) is a major contributor to cardiovascular morbidity and mortality worldwide. This condition is associated with delayed diagnosis and high comorbidity burden since patients often present at a younger age with advanced disease. Echocardiography plays a central role in identifying structural abnormalities and prognostic markers. This study aimed to evaluate the clinical and echocardiographic profile of patients with HFrEF and assess outcome predictors in a tertiary care center. STUDY: A retrospective observational study was conducted at Madras Medical College from May 2024 to May 2025, including 75 patients diagnosed with HFrEF (left ventricular ejection fraction (LVEF) ≤40%). Clinical data on demographics, comorbidities, and New York Heart Association (NYHA) functional class were collected along with echocardiographic parameters such as left ventricular dimensions, diastolic dysfunction, valvular lesions, right ventricular function, and pulmonary artery systolic pressure (PASP). Outcomes assessed included mortality, hospital stay, and readmission.
resultsThe mean age was 58.4 ± 11.2 years, with males comprising 45 patients (60%). Hypertension (42 patients, 56%), diabetes (36 patients, 48%), and ischemic cardiomyopathy (39 patients, 52%) were predominant. Most patients presented in NYHA class III or IV (55 patients, 73%). Echocardiography revealed a mean LVEF of 31.6 ± 5.8, LV dilatation in 48 patients (64%), diastolic dysfunction in 60 patients (80%), and moderate-to-severe mitral regurgitation in 25 patients (33%). Patients with EF <25% had significantly higher mortality (five patients, 15%) and readmission (10 patients, 29%) rates. PASP >40 mmHg independently predicted readmissions, while right ventricular dysfunction and mitral regurgitation were associated with adverse outcomes on univariate analysis.
conclusionsThis study highlights that severe left ventricular dysfunction and elevated PASP are strong prognostic markers in HFrEF. Comprehensive echocardiographic evaluation is essential for risk stratification, and early intervention is crucial to improve outcomes in Indian patients with HFrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.